#### Section I

## Notice of Development of Proposed Rules and Negotiated Rulemaking

#### DEPARTMENT OF HEALTH

#### **Board of Medicine**

RULE NO.: RULE TITLE:

64B8-31.012 Fees Regarding Anesthesiologist Assistants PURPOSE AND EFFECT: The Board proposes the development of rule amendments to address an extension of the fee reductions in the application, initial licensure, and renewal fees for anesthesiologist assistants until February 1, 2021.

SUBJECT AREA TO BE ADDRESSED: Extension of the current fee reductions until February 1, 2021.

RULEMAKING AUTHORITY: 456.013(2), 456.025(10), 456.036(4), (7), (8), 458.309, 458.3475 FS.

LAW IMPLEMENTED: 456.013(2), 456.025(10), 456.036(4), (5), (7), (8), 456.065(3), 458.3475 FS.

IF REQUESTED IN WRITING AND NOT DEEMED UNNECESSARY BY THE AGENCY HEAD, A RULE DEVELOPMENT WORKSHOP WILL BE NOTICED IN THE NEXT AVAILABLE FLORIDA ADMINISTRATIVE REGISTER.

THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE DEVELOPMENT AND A COPY OF THE PRELIMINARY DRAFT, IF AVAILABLE, IS: Claudia Kemp, Executive Director, Board of Medicine/MQA, 4052 Bald Cypress Way, Bin #C03, Tallahassee, Florida 32399-3253.

THE PRELIMINARY TEXT OF THE PROPOSED RULE DEVELOPMENT IS AVAILABLE AT NO CHARGE FROM THE CONTACT PERSON LISTED ABOVE.

#### DEPARTMENT OF HEALTH

#### **Board of Osteopathic Medicine**

RULE NO.: RULE TITLE:

64B15-7.012 Fees Regarding Anesthesiologist Assistants PURPOSE AND EFFECT: The Board proposes the development of rule amendments to address an extension of the fee reductions in the application, initial licensure, and renewal fees for anesthesiologist assistants until February 1, 2021.

SUBJECT AREA TO BE ADDRESSED: Extension of the current fee reductions until February 1, 2021.

RULEMAKING AUTHORITY: 456.013(2), 456.025(10), 456.036(4), (7), (8), 459.005, 459.023 FS.

LAW IMPLEMENTED: 456.013(2), 456.025(10), 456.036(4), (5), (7), (8), 456.065(3), 459.023 FS.

IF REQUESTED IN WRITING AND NOT DEEMED UNNECESSARY BY THE AGENCY HEAD, A RULE DEVELOPMENT WORKSHOP WILL BE NOTICED IN THE NEXT AVAILABLE FLORIDA ADMINISTRATIVE REGISTER.

THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE DEVELOPMENT AND A COPY OF THE PRELIMINARY DRAFT, IF AVAILABLE, IS: Kama Monroe, Executive Director, Board of Osteopathic Medicine/MQA, 4052 Bald Cypress Way, Bin #C06, Tallahassee, Florida 32399-3256.

THE PRELIMINARY TEXT OF THE PROPOSED RULE DEVELOPMENT IS AVAILABLE AT NO CHARGE FROM THE CONTACT PERSON LISTED ABOVE.

#### DEPARTMENT OF HEALTH

#### **Board of Osteopathic Medicine**

RULE NO.: RULE TITLE:

64B15-14.007 Standard of Care for Office Surgery

PURPOSE AND EFFECT: The Board proposes the development of rule amendments to address high-risk procedures in office surgery settings.

SUBJECT AREA TO BE ADDRESSED: Review of the rule for possible amendments related to the performance of high-risk procedures in office surgery settings.

RULEMAKING AUTHORITY: 459.005, 459.015(1)(z), 459.026 FS.

LAW IMPLEMENTED: 459.015(1)(g), (x), (z), (aa), 459.026 FS.

IF REQUESTED IN WRITING AND NOT DEEMED UNNECESSARY BY THE AGENCY HEAD, A RULE DEVELOPMENT WORKSHOP WILL BE NOTICED IN THE NEXT AVAILABLE FLORIDA ADMINISTRATIVE REGISTER.

THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE DEVELOPMENT AND A COPY OF THE PRELIMINARY DRAFT, IF AVAILABLE, IS: Kama Monroe, J.D., Executive Director, Board of Osteopathic Medicine/MQA, 4052 Bald Cypress Way, Bin #C06, Tallahassee, Florida 32399-325.

THE PRELIMINARY TEXT OF THE PROPOSED RULE DEVELOPMENT IS NOT AVAILABLE.

### Section II Proposed Rules

#### DEPARTMENT OF ENVIRONMENTAL PROTECTION

RULE NOS.: RULE TITLES:

62-17.241 Abandonment

PURPOSE AND EFFECT: The purpose and effect of the proposed rule amendment is to repeal Rule 62-17.241, F.A.C. SUMMARY: Rule 62-17.241, F.A.C., directs release of a site from the terms and conditions of a certification order upon a

from the terms and conditions of a certification order upon a finding that such site or portion thereof has been abandoned by the applicant. Deletion of this rule would ensure the Licensee would be required to comply with all applicable non-procedural requirements of state and local agencies related to permanent shutdown or decommissioning of a certified facility.

OTHER RULES INCORPORATING RULE 62-17.241, F.A.C: There are no other rules incorporating this rule.

EFFECT ON THOSE OTHER RULES: There will be no effect on other rules.

SUMMARY OF STATEMENT OF ESTIMATED REGULATORY COSTS AND LEGISLATIVE RATIFICATION:

The Agency has determined that this will not have an adverse impact on small business or likely increase directly or indirectly regulatory costs in excess of \$200,000 in the aggregate within one year after the implementation of the rule. A SERC has not been prepared by the Agency.

The Agency has determined that the proposed rule is not expected to require legislative ratification based on the statement of estimated regulatory costs or if no SERC is required, the information expressly relied upon and described herein: repeal of these rules will not have an adverse impact or increase regulatory costs on any entity.

Any person who wishes to provide information regarding a statement of estimated regulatory costs or provide a proposal for a lower cost regulatory alternative must do so in writing within 21 days of this notice.

RULEMAKING AUTHORITY: 403.504, FS.

LAW IMPLEMENTED: 403.509, FS.

IF REQUESTED WITHIN 21 DAYS OF THE DATE OF THIS NOTICE, A HEARING WILL BE SCHEDULED AND ANNOUNCED IN THE FAR.

THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE IS: Ann Seiler, 2600 Blair Stone Rd., MS 5500, Tallahassee, FL, 32399-2400, ann.seiler@floridadep.gov, (850)717-9113.

THE FULL TEXT OF THE PROPOSED RULE IS:

62-17.241 Abandonment.

Rulemaking Authority 403.504(1), (8) FS. Law Implemented 403.509 FS. History–New 5-7-74, Amended 12-27-77, Formerly 17-17.14(2), Amended 5-9-83, Formerly 17-17.241, Amended 2-1-99, Repealed

NAME OF PERSON ORIGINATING PROPOSED RULE: Cindy Mulkey

NAME OF AGENCY HEAD WHO APPROVED THE PROPOSED RULE: Secretary Noah Valenstein

DATE PROPOSED RULE APPROVED BY AGENCY HEAD: 03/05/2019

#### DEPARTMENT OF CHILDREN AND FAMILIES

#### **Substance Abuse Program**

RULE NO.: RULE TITLE:

65D-30.014 Standards for Medication and Methadone

Maintenance Treatment

PURPOSE AND EFFECT: The Department is filing a Notice of Proposed Rule for Rule 65D-30.014, F.A.C. subsection 397.321(5), F.S., requires the Department to adopt rules necessary to comply with Chapter 397, Substance Abuse Services. Section 397.410, F.S., requires the Department to amend rules in this Chapter to ensure that minimum licensure and best practice standards are met.

SUMMARY: The amendments will accomplish the following: (1) Repeal unnecessary rule language; (2) Revise methodology for determination of need for additional providers; (3) Ensure adequate minimum requirements for licensure of this service; (4) Amend procedures for new provider applicants; and (5) Update general requirements for provider and practitioner standards consistent with clinical and treatment best practices that ensure the provision of quality treatment for individuals receiving substance abuse treatment services.

SUMMARY OF STATEMENT OF ESTIMATED REGULATORY COSTS AND LEGISLATIVE RATIFICATION:

The Agency has determined that this will not have an adverse impact on small business or likely increase directly or indirectly regulatory costs in excess of \$200,000 in the aggregate within one year after the implementation of the rule. A SERC has not been prepared by the Agency.

Any person who wishes to provide information regarding a statement of estimated regulatory costs, or provide a proposal for a lower cost regulatory alternative must do so in writing within 21 days of this notice.

RULEMAKING AUTHORITY: 397.321(5), 397.410(2), FS. LAW IMPLEMENTED: 397.311(26), 397.321, 397.410, 397.427, FS.

A HEARING WILL BE HELD AT THE DATE, TIME AND PLACE SHOWN BELOW:

DATE AND TIME: April 5, 2019, 10:00 a.m. – 12:00 Noon PLACE: (1) Attending in person at: Florida Department of Children and Families, 1317 Winewood Boulevard Building 4, Tallahassee, FL 32399-0700; (2) Via Conference Call Dial: 1(888)585-9008; Code: 946-122-361

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 2 days before the workshop/meeting by contacting: Jodi Abramowitz. Jodi can be reached at (850)717-4470 or Jodi.abramowitz@myflfamilies.com. If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE IS: Jodi Abramowitz. Jodi can be reached at (850)717-4470 or Jodi.abramowitz@myflfamilies.com.

#### THE FULL TEXT OF THE PROPOSED RULE IS:

65D-30.014 Standards for Medication-Assisted and Methadone Maintenance Treatment for Opioid Use Disorders.

In addition to Rule 65D-30.004, F.A.C., <u>subsections (1)</u> through (7) of this rule the following standards apply to <u>methadone m</u>Medication-assisted and Methadone Maintenance tTreatment. <u>Subsection (8) of this rule applies to all other medication-assisted treatments.</u>

- (1) State Authority. The state authority is the  $\underline{De}$ epartment's  $\underline{Office}$  Substance Abuse and Mental Health Program Office.
  - (2) No change.
  - (3) Determination of Need
- (a) The Department shall annually perform the assessment detailed in the "Methodology of Determination of Need Methodone Medication-Assisted Treatment," CF-MH 4038, (insert date), incorporated by reference and available at <a href="http://www.flrules.org/Gateway/reference.asp?No=Ref-XXX">http://www.flrules.org/Gateway/reference.asp?No=Ref-XXX</a>. The <u>D</u>department shall publish the results of the assessment in the Florida Administrative Weekly Register by June 30.

Criteria. New providers shall be established only in response to the department's determination of need, which shall occur annually. The determination of need shall only apply to medication and methadone maintenance treatment. In its effort to determine need, the department shall examine information on treatment, the consequences of the use of opioids (e.g., arrests, deaths, emergency room mentions, other incidence and prevalence data that may have relevance at the time, etc.), population and data on treatment accessibility.

(b) Procedure. The publication shall direct interested parties to submit a letter of intent to apply applications for licensure to provide medication-assisted treatment for opioid use disorders to the Regional Office of Substance Abuse and

Mental Health department's district office where need has been demonstrated.

- <u>1. The publication</u> and shall provide a closing date for submission of <u>letters of intent</u> applications.
- 2. Applicants must identify the fiscal year of the needs assessment to which they are responding in their letter of intent.
- (c) Within seven (7) business days of the closing date, the Regional Office shall notify parties who submitted a letter of intent on how to proceed.
- 1. If the number of letters of intent equals or is less than the determined need, parties shall be awarded the opportunity to proceed to licensure by completing an "Application for Licensure to Provide Substance Abuse Services" form, C&F-SA Form 4024, (insert date,), incorporated by reference and available at http://www.flrules.org/Gateway/reference.asp?No=Ref-XXX.
- 2. If the number of letters of intent exceeds the determined need, parties shall be invited to submit a "Methadone Medication-Assisted Treatment (MAT) Application to Proceed to Licensure Application" form, CF-MH 4041, (insert date), incorporated by reference and available at <a href="http://www.flrules.org/Gateway/reference.asp?No=Ref-XXX">http://www.flrules.org/Gateway/reference.asp?No=Ref-XXX</a>. Applications may not be rolled over for consideration in response to a needs assessment published in a different year and may only be submitted for a current fiscal year needs assessment.
- a. The Department shall utilize an evaluation team made up of industry experts to conduct a formal rating of applications as stipulated in the "Methadone Medication-Assisted Treatment (MAT) Application Evaluation" form, CF-MH 4040, (insert date), incorporated by reference and available at <a href="http://www.flrules.org/Gateway/reference.asp?No=Ref-XXX">http://www.flrules.org/Gateway/reference.asp?No=Ref-XXX</a>. The evaluation team members shall not be affiliated with the Department, current methadone medication-assisted treatment providers operating in Florida, or the applicants.
- <u>b. The selection of a provider shall be based on the following criteria:</u>
- (I) Capability to Serve Selected Area(s) of Need and Priority Populations. Area(s) of Need are the counties identified as having a need for additional clinics. Priority Populations are pregnant women, women with young children, and individuals with financial hardships;
  - (II) Patient Safety and Quality Assurance/Improvement;
- (III) Scope of Methadone Medication-Assisted Treatment Services;
  - (IV) Capability and Experience; and
  - (V) Revenue Sources.
- c. Applicants with the highest-scored applications in each county shall be awarded the opportunity to apply for licensure to meet the need of that county. Regional offices shall inform the highest-scoring applicants in writing of the award.

- d. All awarded applicants must submit a letter of intent to apply for licensure to the appropriate regional office within 30 calendar days after the award. If an applicant declines an award or fails to submit the letter of intent within the specified time, the Department shall rescind the award. After the Department rescinds the original award for that selected area of need, the applicant with the next highest score shall receive the award.
- (d) Awarded applicants must receive at least a probationary license within two (2) years of the published needs assessment connected to their application. See Rule 65D-30.0036, F.A.C. for licensure application requirements. Applicants may submit a request to the State Authority and Substance Abuse and Mental Health Program Office for an exception if unable to meet timeframes due to a natural disaster that causes physical damage to the applicant's building(s). Proof of natural disaster and impact on physical property must accompany the request. Upon receipt of the request for exception and accompanying proof, a one-time extension shall be granted for six (6) months.

The district office shall conduct a formal rating of applicants on a form\_titled MEDICATION AND MAINTENANCE TREATMENT NEEDS ASSESSMENT, September 6, 2001, incorporated herein by reference. The form may be obtained from the Department of Children and Family Services, Substance Abuse Program Office, 1317 Winewood Boulevard, Tallahassee, Florida 32399 0700.

Should the number of responses to the publication for a new provider exceed the determined need, the selection of a provider shall be based on the following criteria:

- 1. The number of years the respondent has been licensed to provide substance abuse services;
- 2. The organizational capability of the respondent to provide medication and methadone maintenance medication assisted treatment in compliance with these rules; and
- 3. History of substantial noncompliance by the respondent with departmental rules;
  - (4) General Requirements.
- (a) Methadone Medication-Assisted Treatment Program or Methadone Maintenance Sponsor. The sponsor, as defined in subsection 65D-30.002(42), F.A.C., of a new provider shall be a licensed health professional and shall have worked in the field of substance use abuse treatment at least five (5) years. The sponsor is responsible for the program operation and assumes responsibility for all its employees, including any practitioners, agents, or other persons providing medical, rehabilitative, or counseling services at the program or any of its medication units. The program sponsor need not be a licensed physician but shall employ a licensed physician for the position of medical director.
- (b) Medical Director. The medical director of a provider shall have a minimum of <u>two (2)</u> years' experience <u>treating</u> <u>substance use disorders.</u> in the field of substance abuse.

- (c) Special Permit and Consultant Pharmacist.
- 1. Special Permit.
- a. All <u>providers</u> facilities that distribute methadone or other medication shall obtain a special pharmacy permit from the State of Florida Board of Pharmacy. New applicants shall be required to obtain a special pharmacy permit prior to licensure by the Ddepartment.
  - b. No change.
- 2. Consultant Pharmacist. The responsibilities of the consultant pharmacist include the following:
- a. Develop <u>policies and</u> operating procedures relative to the supervision of the compounding and dispensing of all medications drugs dispensed in the facility; elinic.
  - b. Provide ongoing pharmaceutical consultation;
- c. Develop operating procedures for maintaining all medication drug records and security in the area within the facility in which the compounding, storing, and dispensing of medications medicinal drugs will occur;
- d. Meet face-to-face, at least quarterly, with the medical director to review the provider's pharmacy practices. Meetings shall be documented in writing and signed and dated by both the consultant pharmacist and the medical director;
- e. Prepare written reports regarding the provider's level of compliance with established pharmaceutical procedures. Reports shall be prepared at least semi-annually and submitted, signed, and dated by the consultant pharmacist and submitted to the medical director; and:
- f. <u>Physically v-Visit</u> the <u>provider facility</u> at least every <u>two</u> (2) weeks to ensure that established procedures are being followed, unless otherwise stipulated by the state Board of Pharmacy. A log of such visits shall be maintained, <u>and</u> signed, and dated by the consultant pharmacist at each visit.
- 3. Change of Consultant Pharmacist. The provider's medical director shall notify the Board of Pharmacy within 10 days of any change of consultant pharmacists, and provide a copy of such notification to the Substance Abuse and Mental Health Program Office and the State Opioid Treatment Authority (SOTA).
- (d) <u>Providers shall develop policies and procedures for the treatment of pregnant women.</u> <u>Pregnancy and Medication and Methadone Maintenance.</u>

#### 1. Use of Methadone.

1. Prior to the initial dose, each female elient shall be fully informed of the possible risks of taking and not taking from the use of methadone during pregnancy, including possible adverse effects on the mother or fetus. and shall be told that safe use in pregnancy has not been established in relation to possible adverse effects on fetal development. If the medication is not taken, risk includes withdrawal syndrome which has been associated with fetal demise. The individual elient shall sign and date a statement acknowledging this information. Pregnant

- women shall be seen by the physician or their qualified designee as clinically advisable. The physician or qualified medical designee must document in the clinical record that the pregnant individual was informed of the risks in this paragraph.
- 2. Pregnant <u>individuals</u> elients shall be informed of the opportunity <u>and need</u> for prenatal care either by the provider or by referral to other publicly or privately funded health care providers. <u>In any event, tThe</u> provider shall establish a <u>documented</u> system for referring <u>individuals</u> elients to prenatal care.
- 3. In the event If there are no publicly funded prenatal referral resources to serve those who are indigent, or if the provider cannot provide such services, or if the client individual refuses the services, the provider shall offer her basic prenatal instruction on maternal, physical, and dietary care as part of its counseling service. The nature of prenatal support shall be documented in the clinical elient record.
- 4. When the individual If the client is referred for prenatal services, the practitioner to whom she is referred shall be notified that she is undergoing methadone maintenance medication-assisted treatment and provided treatment plans addressing pregnancy and post-partum care. Documentation of referral shall be kept in the clinical record. If a pregnant individual elient refuses prenatal care or referral and prenatal instruction and counseling, the provider shall obtain a signed statement from the individual elient acknowledging that she had the opportunity for the prenatal care but declined refused it.
- <u>5.</u> The physician shall sign or countersign and date all entries related to prenatal care.
- 6. Treating physicians or their qualified designee shall consult with other treating medical staff providing care and medications to ensure that prescribed medication protocols are not contraindicated.
- 2. Use of Other Medication. Providers shall adhere to the prevailing federal and state requirements regarding the use of medication other than methadone in the maintenance treatment of clients who are or become pregnant.
- (e) Minimum Responsibilities of the Physician. Physicians must adhere to best practice standards for an individual receiving methadone medication-assisted treatment. Best practices mean practices that meet or exceed the standards established by nationally-recognized, research-validated substance use disorder-specific program standards regarding the types of services, hours of clinical care, and credentials of staff for levels of care. In addition, tThe responsibilities of the physician include the following:
- 1. To ensure that evidence of current physiological addiction, history of addiction, and exemptions from criteria for admission are documented in the <u>clinical</u> <u>client</u> record before the <u>individual</u> <u>client</u> receives the initial dose of <u>methadone or other</u> medication;

- 2. To sign or countersign and date all medical orders, including the initial prescription, all subsequent prescription changes, <u>and</u> all changes in the frequency of take-home <u>medication</u>; <u>methadone</u>, <u>and the prescription of additional take-home doses of methadone in cases involving the need for exemptions</u>.
- 3. To ensure that justification is recorded in the <u>clinical</u> elient record for <u>any change to the reducing the frequency of</u> visits to the provider for observed <u>medication drug</u> ingesting, providing additional take home methadone in cases involving the need for exemptions, including cases involving the need for exemptions, or when prescribing medication for physical or emotional problems; and
- 4. To review, sign or countersign, and date treatment plans at least annually; and-
- 5. To ensure that a face-to-face assessment is conducted with each <u>individual</u> elient at least annually, including evaluation of the <u>individual's physical/medical status</u>, elient's progress in treatment, and justification for continued maintenance or medical clearance for voluntary withdrawal or a dosage reduction protocol. The assessment shall be conducted by a physician or a P.A. or A.R.N.P. under the supervision of a physician. If conducted by other than a physician, the assessment shall be reviewed and signed by a physician in accordance with the medical protocol established in subsection 65D 30.004(7), F.A.C. The protocol shall include criteria and the conditions under which the assessment would be conducted more frequently.
  - (f) Central Client Registry.
- 1. Providers shall register and participate in the Department-approved electronic regional registry system for individuals receiving methadone medication-assisted treatment services. The registry is used to prevent the enrollment of individuals at more than one (1) provider and to facilitate continuity of care in the event of program closure and guest dosing verification. The registry shall be implemented in compliance with 42 Code of Federal Regulations, Part 2. The provider must submit to information gathering activities by the SOTA for state planning purposes. activities for the purpose of sharing client identifying information with other providers located within a 100 mile radius, to prevent the multiple enrollment of clients in more than one provider. Each regional registry shall be conducted through an automated system where this capability exists. In those instances where the development and implementation of an automated system would require additional technology, an alternative method shall be used on an interim basis, as long as the alternative is implemented in compliance with 42 Code of Federal Regulations, Part 2, and approved by the state authority shall designate a provider.
- 2. Providers must maintain the registry by recording and updating identifying, demographic, emergency contact, dosing,

and relevant medical information for all individuals receiving methadone medication-assisted treatment.

- a. Each business day, providers shall monitor individuals enrolled in more than one (1) site and discharge any individuals attempting to enroll in another location. Individuals shall not be dual enrolled in any two (2) locations for longer than three (3) days. Providers shall monitor the following reports quarterly to ensure compliance with no higher than a five (5) percent rate for missing data for the following data reports:
  - (I) Missing Photos;
  - (II) Missing Zip Codes;
  - (III) Missing Dosing Summary;
  - (IV) Missing Mileage Information;
  - (V) Missing County Information;
  - (VI) Missing Emergency Medication Information;
- b. Providers shall monitor the following reports quarterly and ensure data is accurate:
- (I) Pregnancy Status. Providers must maintain accurate data on pregnancy status.
- (II) Emergency Consent. Providers must make monthly attempts to add emergency contact for individuals who have not provided consent to be contacted during an emergency facility closure. Refusals must be documented. Providers shall ensure accuracy of emergency contact information quarterly.
- (III) Emergency Dosing Projected Inventory Requirements. Providers must ensure they maintain an inventory of methadone onsite to dispense in the event of a natural or manmade disaster.

Providers may volunteer to coordinate the registry activities or, in the event that no provider volunteers, the state authority shall designate a provider.

- 3. Program directors must certify monthly, via the Central Registry, the accuracy of census data. Providers shall submit, with the application for licensure, written plans for participating in registry activities.
- 4. Methadone or other medication shall not be administered or dispensed to an individual a client who is known to be currently enrolled with participating in another provider. 5. The individual client shall always report to the same provider unless prior approval is obtained from the original provider for treatment at another provider. Permission to report for treatment with at the facility of another provider shall be granted only when the multi-disciplinary treatment team, in their professional judgement, determine it is in the best interest of the individual. The permission, supporting clinical documentation, and evidence of linkage to care in exceptional circumstances and shall be noted in the clinical client's record. Upon notification that an individual is being admitted to a new provider, it is the responsibility of the original admission site to discharge an individual from the Central Registry.
  - <u>56</u>. Individuals applying for <u>methadone medication</u>-

<u>assisted</u> maintenance treatment shall be informed of the registry procedures and shall be required to sign a consent form before receiving services. Individuals who apply for services and do not consent to the procedures will not be <u>enrolled</u> placed in medication assisted treatment maintenance.

- 67. If an individual is found trying to secure or has succeeded in obtaining duplicate doses of methadone or other medication, the <u>individual elient</u> shall be referred back to the original provider. A written statement documenting the incident shall be forwarded to the original provider <u>and</u>, if the individual succeeded in obtaining the duplicate dose, the incident must be reported in the Department-approved incident reporting system by the provider who dispensed the duplicate dose. The physician of the original provider shall evaluate the <u>individual elient</u> as soon as medically feasible for continuation of treatment. In addition, a record of violations by <u>individuals individual elients shall must</u> become part of the <u>clinical</u> record maintained <u>by all participating providers</u> and shall be made available to Department staff upon request <u>in an automated system and permit access by all participating providers</u>.
- 7. Providers shall submit with the application for licensure written plans for participating in registry activities, maintaining accurate data on staff and individuals in treatment, and ensuring annual training for all staff on reporting and disaster preparedness procedures.
- 8. It is the responsibility of the SOTA to run quarterly reports to identify providers with missing data related to patient identification, dosage information, dual enrollment, pregnancy outcomes, and demographic information. Providers with a higher than five (5) percent non-compliance rate (missing or inaccurate data) will be contacted by the SOTA and/or licensure staff. Pursuant to s. 397.415, F.S., a Class IV fine will be imposed on those providers who do not correct non-compliance issues within five (5) days.
- 9. Prior to conducting an inspection or program review, an authorized agent of the Department shall contact the SOTA to obtain a compliance report. Non-compliance shall be incorporated into inspection reports and included in corrective action plans.
  - (g) Wait lists.
- 1. Providers must maintain wait list data for individuals seeking care but unable to enroll within 24 hours of first
  - contact requesting initiation of treatment.
- 2. When an opening is available, providers must make at least one (1) attempt to contact the next prospective individual on the waiting list and maintain a system of documenting attempts. Documentation shall include at a minimum: date of attempted contact, individual's name, date of birth, address, and contact information.
- 3. Priority must be given to pregnant woman and HIV-positive individuals.

(h)(g) Operating Hours and Holidays

- 1. Providers shall post operating hours in <u>full view of the public</u> a conspicuous place within the facility. This information shall include hours for counseling and <u>administering</u> medication <u>medicating clients</u>.
- 2. All providers shall be open Monday through Saturday. Providers shall have medicating hours and counseling hours that accommodate <u>individuals</u> elients, including two (2) hours of medicating time accessible daily outside the hours of 9:00 a.m. to 5:00 p.m.
- 3. Providers are required to medicate on Sundays according to the needs of the individual elient's needs. This includes individuals would include clients on Phase 1, individuals elients on a 30 to 180-day detoxification regimen, and individuals elients who need daily observation. Providers The provider shall develop operating policies and procedures for Sunday coverage.
- 4. In case of impending disaster, providers shall implement disaster preparedness policies and procedures as necessary regarding operating hours and dosing.
- <u>5.</u> When holidays are observed, all <u>individuals</u> elients shall be given a minimum of a <u>seven (7)</u>-day notice <u>of any changes</u> to the hours of operation.
- 6. When applying for a license, providers shall inform the respective <u>program district</u> offices of their intended holidays. In no case shall two (2) or more holidays occur in immediate succession unless the provider is granted an exemption by the <u>state and</u> federal authority. Take-out privileges shall be available to all <u>eligible individuals methadone clients</u> during holidays, <u>but only</u> if clinically advisable. On those days during which the provider is closed, <u>Services shall be accessible to individuals elients</u> for whom take-home medication out methadone is not clinically advisable. <u>Individuals Clients</u> who fall into this category shall receive a minimum of seven (7) days adequate notification regarding <u>arrangements and</u> the exact hours of operation.
  - (5) Maintenance Treatment Standards.
  - (a) Standards for Placement.
  - 1. Determining Addiction and Placement.
- a. An individual A person aged 18 or over shall be placed in treatment as a client only if the physician, or their qualified designee identified in accordance with the medical protocol established in subsection 65D-30.004(7), F.A.C., determines that the individual person is currently physiologically addicted to opioid drugs and became physiologically addicted at least one (1) year before placement in methadone medication-assisted maintenance treatment.
- <u>b.</u> A <u>one (1)-year</u> history of addiction means that <u>individuals seeking</u> an <u>applicant for</u> placement in <u>methadone</u> <u>medication-assisted</u> <u>maintenance</u> treatment <u>were</u> <u>was</u> physiologically addicted to opioid drugs at least <u>one (1)</u> year

before placement and were was addicted continuously or episodically for most of the year immediately prior to placement with in a provider.

- c. In the event the exact date of physiological addiction cannot be determined, the physician or their qualified designee may admit the individual person to maintenance treatment if, by the evidence presented and observed, and utilizing reasonable clinical judgment, the physician or their qualified designee concludes it is reasonable to conclude that the individual person was physiologically addicted during the year prior to placement. Such observations shall be recorded in the clinical elient record by the physician or their qualified designee. Participation in treatment must be voluntary.
- d. Individuals with a chronic immune deficiency or who are pregnant must be screened and admitted on a priority basis.
- e. Individuals seeking admission with only a primary medical diagnosis of a chronic pain condition must be referred to specialists qualified to treat chronic pain conditions and are not eligible for admission.
  - 2. Placement of Individuals Under 18 Years of Age
- a. An individual A person under 18 is required to have had two (2) documented unsuccessful attempts at short-term detoxification or <u>substance use</u> drug free treatment within the last year to be eligible for maintenance treatment.
- <u>b.</u> The physician <u>or their qualified designee</u> shall document in the <u>clinical elient's</u> record that the <u>individual elient</u> continues to be or is again physiologically dependent on opioid drugs and is appropriate for placement. No person under 18 years of age shall be placed in maintenance treatment unless a parent, legal guardian, or responsible adult provides written consent.
- c. Treatment standards in this rule are not intended to limit current best practice protocols for this population.
  - 3. Evidence of Addiction.
- <u>a.</u> In determining the current physiological addiction of the <u>individual elient</u>, the physician <u>or their qualified designee</u> shall consider signs and symptoms of drug intoxication, evidence of use of drugs through a urine drug screen, and needle marks.
- <u>b.</u> Other evidence of current physiological dependence shall be considered by noting early signs of withdrawal, such as <u>cramping</u>, lachrymation, rhinorrhea, pupillary dilation, pilo erection, body temperature, pulse rate, <u>elevated</u> blood pressure, and <u>increased</u> respiratory rate.

#### (b) Individual Consent.

- 1. Individuals shall be advised of the benefits of therapeutic and supportive rehabilitative services, and that the goal of methadone medication-assisted treatment is stabilization of functioning. The individual shall be fully informed of the risks and consequences of methadone medication-assisted treatment.
- 2. Each provider shall provide a thorough explanation of all program services, as well as state and federal policies and regulations, and obtain a voluntary, written, and signed

program-specific statement of fully informed consent from the individual at admission.

- 3. In full consultation with the individual, the counselor shall discuss present level of functioning, course of treatment, and future goals. Consultations shall occur, at a minimum, quarterly for individuals in year one of treatment, and, at a minimum, bi-annually for individuals in treatment longer than one (1) year. These discussions should not place pressure on the individual to withdraw from or to remain in methadone medication-assisted treatment, unless medically or clinically indicated. Acknowledgement of these discussions shall be documented in the clinical record.
- 4. No individual under 18 years of age shall be placed in methadone medication-assisted treatment unless a parent or legal guardian provides written consent.
  - (c)(b) Exemption from Minimum Standards for Placement.
- 1. An individual A person who has resided in a penal or chronic-care institution for one (1) month or longer may be placed in maintenance treatment within 14 days before release or within 6 months after release from such institution. This can occur without documented evidence to support findings of physiological addiction, providing the individual person would have been eligible for placement before incarceration or institutionalization, and in the reasonable clinical judgment of the physician or their qualified designee, methadone medication-assisted treatment is medically justified.
- <u>2. Documented Ee</u>vidence of prior residence in a penal or chronic-care institution, evidence of all other findings, and the criteria used to determine the findings shall be recorded by the physician <u>or their qualified designee</u> in the <u>clinical</u> <u>elient</u> record.
- 3. The physician <u>or their qualified designee</u> shall sign and date these <u>entries</u> <del>recordings</del> before the initial dose is administered.

#### (d) Pregnant individuals.

- 12. Pregnant individuals elients, regardless of age, who have had a documented addiction to opioid drugs in the past and who may be in direct jeopardy of returning to opioid drugs, may be placed in methadone medication-assisted treatment. with all its attendant dangers during pregnancy, may be placed in maintenance treatment. For such individuals elients, evidence of current physiological addiction to opioid drugs is not needed if a physician or their qualified designee certifies the pregnancy and, in utilizing reasonable clinical judgment, finds treatment to be medically justified.
- <u>2.</u> Pregnant <u>individuals</u> <u>elients</u> may be placed on a <u>medication-assisted</u> <u>maintenance</u> treatment regimen using a medication other than methadone only upon the written order of the physician who determines this to be the best choice of therapy for that individual <u>elient</u>.
  - 3. Documented Eevidence of current or prior addiction and

criteria used to determine such findings shall be recorded in the <u>clinical elient</u> record by the admitting physician <u>or their qualified designee</u>. The physician <u>or their qualified designee</u> shall sign and date these recordings prior to administering the initial dose.

#### (e) Readmission to Treatment.

- 13. Up to 2 years after discharge or detoxification for opioid use disorders, an individual a client who has been previously involved in methadone medication-assisted maintenance treatment may be readmitted without evidence to support findings of current physiological addiction. This can occur if the provider is able to document prior maintenance treatment of six (6) months or more and the physician or their qualified designee, utilizing reasonable clinical judgment, finds readmission to maintenance treatment to be medically justified.
- 2. Evidence of prior treatment and the criteria used to determine such findings shall be recorded in the <u>clinical</u> elient record by the physician or <u>their qualified designee</u>. The physician <u>or their qualified designee</u> shall sign and date the information recorded in the <u>clinical</u> elient record. The provider shall not place a client on a maintenance schedule unless the physician has determined that the client is unable to be admitted for services other than maintenance treatment.

(f)(c) Denying an Individual a Client Treatment.

1. If an individual a client will not benefit from a treatment regimen that includes the use of methadone or other opioid treatment medications medication, or if treating the individual elient would pose a danger to others other clients staff, or other individuals, the individual elient may be refused treatment. This is permitted even if the individual elient meets the standards for placement. The physician or their qualified designee shall make this determination and shall document the basis for the decision to refuse treatment.

(g)(d) Methadone Take-home Privileges.

- 1. Take-home doses <u>of methadone</u> are permitted only for <u>individuals elients</u> participating <u>in a methadone medication-assisted treatment program</u> on a <u>methadone maintenance regimen</u>. Requests for take-home doses greater than the amount <u>allowed</u>, as stipulated in subparagraph (5)(h) of this rule, must be entered into the <u>SAMHSA/CSAT</u> Opioid Treatment <u>Program Extranet for federal and state approval</u>. The following must be indicated on the exception request:
- a. Dates of Exception: not to exceed a six (6) month period of time per request;
  - b. Justification;
- c. Dates and results of last three (3) drug screens, for individuals in treatment longer than 90 days;
- d. Indicate compliance with securing methadone in a lockable secure container;
  - e. Statement of supporting documentation on file; and
  - f. Any other information the provider deems necessary in

support of the request.

- 2. Take home doses of methadone may be granted if the elient meets the following conditions:
- a. Absence of recent abuse of drugs as evidenced by drug screening;
  - b. Regularity of attendance at the provider;
  - c. Absence of serious behavioral problems at the provider;
- d. Absence of recent criminal activity of which the program is aware, including illicit drug sales or possession;
- e. Client's home environment and social relationships are stable;
- f. Length of time in methadone maintenance treatment meets the requirements of paragraph (e);
- g. Assurance that take home medication can be safely stored within the client's home or will be maintained in a locked box if traveling away from home;
- h. The client has demonstrated satisfactory progress in treatment to warrant decreasing the frequency of attendance; and
  - i. The client has a verifiable source of legitimate income.
- 2. The medical director shall make determinations based on take-home criteria as stated in 42 CFR 8.12(i)(2).
- 3. When considering <u>an individual's</u> elient responsibility in handling methadone, the physician shall consider the recommendations of other staff members who are most familiar with the relevant facts regarding the individual elient.
- 4. The requirement of time in treatment <u>and participation</u> is a minimum reference point after which <u>an individual a client</u> may be eligible for take-home privileges. The time <u>in treatment</u> reference is not intended to mean that <u>an individual client</u> in treatment for a particular length of time has a right to take-home methadone. Thus Regardless of time in treatment, the physician, <u>state or federal authorities</u> with cause, may deny or rescind the take-home <u>methadone</u> privileges of <u>an individual a client</u>.
- 5. In the event of a disaster that prompts a program-wide exemption authorized by SAMHSA and the SOTA in advance, providers must make appropriate arrangements for unstable individuals. In the event there are medically unstable individuals, providers are responsible for contacting guest dosing centers (i.e. hospitals) in advance to ensure continuity of care. Providers shall make an effort to identify and provide individuals a list of nearby emergency shelters that will allow individuals to bring medication in a lockable secure container.
- (h)(e) Take-home Phases. To be considered for take-home privileges, <u>all individuals</u> elients shall be in compliance with criteria as stated in 42 CFR 8.12(i)(2) subparagraph (d)2.
- 1. Differences in the nature of abuse potential in opioid treatment medications determine the course of treatment and subsequent take-home privileges available to the individual based on progress, participation, and circumstances. The

- assessment and decision approving all take-homes shall be documented in the individual's clinical record, signed and dated by the physician.
- <u>2.</u> No take-homes shall be permitted during the first 30 days following placement unless approved by <u>both</u> the state <u>and federal authorities</u> <u>authority</u>.
- <u>a</u>4. Phase I. Following 30 consecutive days in treatment, the <u>individual elient</u> may be eligible for <u>one (1)</u> take-home per week from day 31 through day 90, provided that the <u>individual elient</u> has had negative drug screens <u>and is following program</u> requirements for the preceding 30 days.
- <u>b2</u>. Phase II. Following 90 consecutive days in treatment, the <u>individual</u> <del>elient</del> may be eligible for <u>two (2)</u> take-homes per week from day 91 through day 180, provided that the <u>individual</u> <del>elient</del> has had negative drug screens for the preceding 60 days.
- <u>c3</u>. Phase III. Following 180 consecutive days in treatment, the <u>individual elient</u> may be eligible for <u>three (3)</u> take-homes per week with no more than a <u>two (2)</u>-day supply at any one time from day 181 through <u>one (1)</u> year, provided that the <u>individual elient</u> has had negative drug screens for the preceding 90 days.
- <u>d</u>4. Phase IV. Following <u>one (1)</u> year in <u>continuous</u> treatment, the <u>individual elient</u> may be eligible for <u>four (4)</u> takehomes per week <u>with no more than a 2 day supply at any one time</u> through the second year of treatment, provided that the <u>individual elient</u> has had negative drug screens for the preceding 90 days.
- <u>e</u>5. Phase V. Following <u>two</u> (2) years in <u>continuous</u> treatment, the <u>individual-elient</u> may be eligible for <u>five</u> (5) takehomes per week <u>with no more than a 3 day supply at any one time</u>, provided that the <u>individual elient</u> has had negative drug screens for the preceding 90 days.
- <u>f6</u>. Phase VI. Following <u>three (3)</u> years in treatment, the <u>individual elient</u> may be eligible for <u>six (6)</u> take-homes per week provided that the <u>individual had elient has passed</u> all negative drug screens for the past year.
- 3.(f) Methadone Medical Maintenance. Providers must receive prior approval in writing from the State Authority to use the medical maintenance protocol. The provider Providers may place an individual a client on methadone medical maintenance in those cases where it can be demonstrated that the potential benefits of medical maintenance to the individual exceed the potential risks, in the professional judgment of the physician. client far exceed the potential risks. Only a physician may authorize placement of an individual a client on medical maintenance. The physician shall provide justification in the clinical client record regarding the decision to place an individual a client on medical maintenance.

The following conditions shall apply to medical maintenance.

a1. To qualify for partial medical maintenance, an

individual a client may receive no more than 13 take-homes and must have been in continuous treatment with the same clinic for four years (4) with negative drug screens for the previous two (2) years. all with at two previous years (2) of negative drug screens.

- <u>b2</u>. To qualify for full medical maintenance <u>an individual</u> a client may receive no more than 27 take-homes and must have been in <u>continuous</u> treatment with the same clinic for five years (5) with <u>negative drug screens for the previous two (2) years. at least three (3) years of negative drug screens.</u>
- <u>c3</u>. All <u>individuals</u> <u>elients</u> in medical maintenance will receive their medication <u>orally</u> in <u>the form of liquid, diskette or tablet.</u> <u>tablet form only</u>. <u>Diskettes and tablets are allowed if formulated to reduce potential parenteral abuse.</u>
- <u>d</u>4. All <u>individuals</u> <del>elients</del> will participate in a "call back" program by reporting back to the provider upon notice <u>for a medication count.</u>
- <u>e</u>5. All criteria for take\_homes as listed under paragraph (5)(g)(d) shall continue to be met.

The provider shall develop operating procedures for medical maintenance.

(i)(g) <u>Transferred Individuals</u> <u>Transfer Clients</u> and Take-Home Privileges.

- 1. Any <u>individual elient</u> who transfers from one (1) provider to another within the state of Florida shall be eligible for placement on the same phase provided that verification of enrollment <u>and compliance with program requirements</u> is received from the previous provider <u>prior to implementing transfer within two weeks of placement</u>. The physician at the previous provider shall also document that the <u>individual elient</u> met all criteria for their current phase and are at least on Phase I.
- 2. Any <u>individual elient</u> who transfers from out-of-state is required to <u>comply with the criteria stated in 42 CFR 8.12(i)(2)</u> meet the requirements of <u>subparagraph (d)2.</u>, and with verification of previous <u>clinical elient</u> records, the physician shall determine the phase level based on the <u>individual's elient's</u> history.

(j)(h) Transfer Information. When <u>an individual</u> a <u>client</u> transfers from one (1) provider to another, the referring provider shall release the following information:

- 1. through 5. No change.
- 6. Documentation of the conditions which precipitated the referral; and
- 7. A written summary of the <u>individual's</u> elient's last <u>three</u> (3) months of treatment;
- 8. Any history of behavioral non-compliance, emotional, or legal problems; and
- 9. A copy of the clinical records to ensure coordination of care, to include: discharge summary, medical assessments, and current medications and dosage. Additional records may be sent

based on their appropriateness to ensure coordination of care. This information shall be released prior to the <u>individual's elient's</u> arrival at the provider to which he or she is transferred. Providers shall not withhold <u>an individual's a elient's</u> records when requested by the <u>individual elient</u> for any reason, including <u>failure to pay bills owed to the provider elient debt</u>. The referring provider shall forward the records directly to the provider of the <u>individual's choosing with signed records</u> releases from the individual <u>elient's choice</u>.

(k)(i) Exemptions from Take-Home Privileges and Phasing Requirements for Methadone Maintained Clients.

- 1. Exemptions for Disability or Illness
- a. If an individual a client is found to have a physical disability which interferes with the individual's client's ability to conform to the applicable mandatory schedule, the individual client may be permitted a temporary or permanently reduced schedule by the physician, and, at the discretion of the SOTA and federal authorities, provided the individual client is also found to be responsible in handling opioid treatment medication, is making progress in treatment, and is providing drug screens free of illicit substances methadone.

<u>b.</u> Providers shall obtain medical records and other relevant information as needed to verify the <u>medical condition physical disability</u>. Justification for the reduced <u>attendance</u> schedule shall be documented in the <u>clinical elient</u> record by the physician <u>or their qualified designee</u> who shall sign and date these entries.

#### 2. Temporary Reduced Schedule of Attendance

<u>a. An individual A client</u> may be permitted a temporarily reduced schedule of attendance because of exceptional circumstances such as illness, personal or family crises, and travel, or other hardship which causes the <u>individual client</u> to become unable to conform to the applicable mandatory schedule. This is permitted only if the <u>individual client</u> is also found to be responsible in handling <u>opioid treatment</u> medication, has consistently provided drug screens free of illicit substances, and has made acceptable progress toward treatment goals methadone.

b. Any individual using prescription opioid medications or sedative medication not used in the medication-assisted treatment protocols shall provide a legitimate prescription from the prescribing physician. The physician, or medical designee, shall consult with the prescribing physician to coordinate care as outlined in medical protocols.

<u>c.</u> The necessity for an exemption from a mandatory schedule is to be based on the reasonable clinical judgment of the physician. and Sauch determination of necessity shall be recorded in the <u>clinical elient</u> record by the physician <u>or their qualified designee</u> who shall sign and date these entries. A client shall not be given more than a 14-day supply of methadone at any one time unless an exemption is granted by

the state methadone authority and by the federal government.

- 3. Travel Distance.
- <u>a.</u> In those instances where <del>elient</del> access to a provider is limited because of travel distance, the physician is authorized to reduce the frequency of <u>an individual's a elient's</u> attendance. This is permitted if the <u>individual elient</u> is currently employed or attending a regionally approved educational or vocational program or the <u>individual elient</u> has regular child-caring responsibilities that preclude daily trips to the provider. <u>This does not extend to individuals who choose to travel further than the closest affordable program to dose.</u>
- <u>b.</u> The reason for reducing the frequency of attendance shall be documented in the <u>clinical</u> <u>elient</u> record by the physician who shall sign and date these entries. <u>These requests shall be reviewed and a decision rendered by state and federal authorities.</u>
  - 4. Other Travel.
- a. Any exemption that is granted to an individual a client regarding travel shall be documented in the clinical client's record. Such documentation shall include tickets prior to a trip, copies of boarding passes, copies of fuel receipts, gas or lodging receipts, or other verification of the individual's client's arrival at the approved destination. If travel is due to medical treatment, documentation shall include a physician's note or related documentation. Generally, special take-homes shall not exceed 27 doses at one (1) time. Request for take-homes in excess of 27 doses must be submitted for approval through SAMHSA/CSAT Opioid Treatment Program Extranet for federal and state approval.
- <u>b. Individuals</u> <u>Clients</u> who receive exemptions for travel shall be required to submit to a drug <u>screening</u> test on the day of return to the <u>provider</u> facility.

(1)(i) Random Drug Screening.

- 1. Individuals in the first six (6) months of treatment shall be required to submit to aAt least one (1) monthly random drug screen, random and monitored, shall be performed on each. The drug screen shall be conducted so as to reduce the risk of falsification of results. This shall be accomplished by direct observation or by another accurate method of monitoring.
- 2. <u>Individuals</u> <u>Clients</u> who are on Phase <u>III or higher</u> <del>VI</del> shall be required to submit to <u>a minimum of eight (8) one</u> random drug <u>screens per year of an individual's treatment plan.</u> <u>screen at least every 90 days.</u>
- 3. All drug screens shall be conducted by direct observation, or by another accurate method of monitoring in order to reduce the risk of falsification of results. Each specimen shall be analyzed for opioids, methodone, buprenorphine, amphetamines, benzodiazepines, and opiates, cocaine, and marijuana. If there is a history of prescription

- opioid analgesic abuse, an expanded toxicology panel that includes these opioids shall administered. Additional testing is based on individual patient need and local drug use patterns and trends.
- 4. The physician shall review all positive drug screens <u>from illicit substances</u> in accordance with the medical protocol established in subsection 65D-30.004(7), F.A.C.
- (m)(k) Employment of Persons on a Maintenance Protocol. No staff member, either full-time, part-time or volunteer, shall be on a maintenance protocol unless a request to maintain or hire staff undergoing treatment is submitted with justification to and approved by the state and federal authorities. Any approved personnel on a maintenance regimen shall not be allowed access to or responsibility for handling methadone or other opioid treatment medication.
- (n)(1) Caseload. No full-time counselor shall have a caseload that exceeds the equivalent of 32 currently participating clients. Participating individual elient equivalents are determined in the following manner.
- 1. An individual A client seen once per week would count as 1.0 elient equivalent.
- 2. An individual A client seen bi-weekly would count as a .5 client equivalent.
- 3. An individual A client seen monthly or less would count as a .25 client equivalent.
- <u>4.</u> As an example, a counselor has <u>a caseload of 15 individuals</u> elients that are seen weekly (counts as <u>15 an</u> equivalent <u>of 15 elients</u>), 30 <u>individuals</u> elients seen biweekly (counts as <u>an 15</u> equivalent <u>of 15 elients</u>), and 8 <u>individuals elients</u> seen monthly (counts as <u>an 2</u> equivalent <u>of 2 elients</u>). The counselor would have a total caseload of 53 <u>individuals individuals</u> elients equaling 32 equivalent <u>individuals</u> elients.

(o)<del>(m)</del> Termination from Treatment.

- 1. There will be occasions when <u>individuals</u> <u>elients</u> will need to be terminated from <u>maintenance</u> treatment. <u>Individuals</u> <u>Clients</u> who fall into this category are those who:
- a. Attempt to sell or deliver their prescribed <u>medication or</u> <u>any other</u> drugs:
- b. Become or continue to be actively involved in criminal behavior:
- c. Consistently fail to adhere to the requirements of the provider;
- d. Persistently use <u>illicit substances</u>; <del>drugs other than methadone,</del> or
  - e. No change.

Such <u>individuals</u> <u>clients</u> shall be withdrawn in accordance with a dosage reduction schedule prescribed by the physician and referred to other treatment, as clinically indicated. This action shall be documented in the <u>clinical</u> <u>client</u> record by the physician.

2. Providers shall establish criteria for involuntary termination from treatment that describe the rights of clients as well as the responsibilities and rights of the provider. All individuals elients shall be given a copy of these criteria upon placement and shall sign and date a statement that they have received the criteria.

(p)(n) Withdrawal from Maintenance.

- 1. The physician shall ensure that all <u>individuals</u> elients in <u>methadone medication-assisted</u> maintenance treatment receive an annual assessment. This assessment may coincide with the annual assessment of the treatment plan and shall include an evaluation of the <u>individual's</u> elient's progress in treatment and the justification for continued maintenance. The assessment and recommendations shall be recorded in the <u>clinical</u> elient record.
- 2. All providers shall develop policies and procedures that allow for systemic withdrawal of individuals as part of on-going services of the program. At least annually, the provider shall provide the individual with documentation that explains the titration of medication to maintain therapeutic levels or to withdraw from the medication with the least necessary discomfort. The provider shall discuss the advantages and potential problems associated with withdrawal. The provider shall document the request for titration in the clinical record with course of action and shall be signed by individual and consulting staff.
- 3. An individual A client being withdrawn from maintenance treatment shall be closely supervised during withdrawal. A dosage reduction schedule shall be established by the physician and documented in the clinical record. In the event withdrawal is clinically inadvisable, justification must be kept in the clinical record, signed and dated by the physician and individual.

(q)(o) Services.

- 1. Comprehensive Services. A comprehensive range of services shall be available to each <u>individual as required in subsection 397.427(1)</u>, F.S. elient. The type of services to be provided shall be determined by <u>individual elient</u> needs, the characteristics of <u>individuals</u> elients served, and the availability of community resources.
  - 2. Counseling.
- a. Each <u>individual receiving methadone medication-assisted treatment</u> elient on maintenance shall receive regular counseling. A minimum of one (1) counseling session per week shall be provided to <u>individuals new clients</u> through the first 90 days. A minimum of two (2) counseling sessions per month shall be provided to <u>individuals elients</u> who have been in treatment for at least 91 days and up to one (1) year. A minimum of one (1) counseling session per month shall be provided to clients who have been in treatment for longer than one (1) year.

- b. If fewer sessions are clinically indicated for a client, this shall be justified and documented in the client record. In no case shall sessions be scheduled less frequently than every 90 days. This would apply\_to those clients who have been with the program longer than three years and have demonstrated the need for less frequent counseling in accordance with documentation in the treatment plan.
- <u>be</u>. A counseling session shall be at least 30 minutes in duration, <u>conducted in a private room</u>, and shall be documented in the <u>clinical elient</u> record.
- c. Any entity or qualified professional who has entered into a written agreement with a licensed provider is bound by these regulations.

#### (r) Overdose Prevention

- 1. All licensed providers must develop overdose prevention plans. Overdose prevention plans must be shared with individuals upon admission and discharge from medication-assisted treatment, regardless of the reason for discharge. Plans must also be shared with individuals placed on a waitlist to receive treatment services. Overdose prevention plans shall include, at a minimum:
- <u>a</u>, Education about the risks of overdose, including having a lower tolerance for opioids once the individual is no longer on medication-assisted treatment;
- b. Information about Naloxone, the medication that reverses opioid overdose, including where and how to access Naloxone in the county of residence;
- c. For providers who maintain an emergency overdose prevention kit, a developed and implemented plan to have staff trained in the prescribed use and the availability of the kit for use during all program hours of operation.
  - (6) Medication Units Satellite Maintenance.
- (a) A provider that currently holds a state license and who has either exceeded site capacity or has a significant proportion of individuals in treatment with a travel burden, may apply to the SOTA to establish a medication unit. The provider must be in compliance with the Department and applicable regulating agencies. The licensed provider and medication unit must be owned by the same provider. satellite maintenance dosing station must be operated by a primary, licensed comprehensive maintenance provider and must meet all applicable regulations in Rule 65D 30.004 and subsection 65D 30.014(4), F.A.C.
- (b) A medication unit's services are limited to medication dosing and drug screening as defined in 42 CFR 8.2 and 42 CFR 8.11(i). In addition to the application for licensure for satellite maintenance, the comprehensive maintenance provider must submit a written protocol containing, at a minimum, a detailed service plan, a staffing pattern, a written agreement with any other organization providing facility or staff, operating procedures, and client eligibility and termination criteria.

- (c) Providers interested in establishing a medication unit must submit a written proposal to the state authority for review and approval. Proposals must include the following for consideration of approval:
- 1. Description of proposed medication unit. Include description of target population, geographical catchment area, physical location/address, proposed capacity, and hours of operation;
- 2. Justification of need for medication unit. Provide explanation on why currently licensed facilities are insufficient and how the proposed medication unit addresses unmet need;
  - 3. Copy of state license and federal certifications;
- 4. Required qualifications and job description for Medical Director, clinical on-site Director or Manager, and proposed staffing for the medication unit;
- 5. Implementation plan, including timeframes for securing federal approvals for a medication unit and anticipated start date of services;
- 6. Plans to secure proper zoning before medication unit opening; and
- 7. Plans on how medication unit will ensure individuals receive comprehensive support services such as counseling.
- 8. An affirmative statement that the primary full-service program agrees to retain responsibility for care;
- 9. An affirmative statement that the medication unit is limited to administering and dispensing the narcotic treatment medications and collecting samples for drug screening or analysis.
- (d) Medication units must open within two (2) years of receiving approval.
- (7) Best Practices. All licensed providers shall comply with best practices as defined in subsection (4)(e) of this rule.
  - (8) Other Medications
- (a) Buprenorphine Products. Qualified medical personnel licensed to practice in the state of Florida and meeting all federal requirements can prescribe buprenorphine to individuals under their license. Medical personnel shall comply with federal regulations related to buprenorphine products.
- (b) Naltrexone Products. Naltrexone can be prescribed by any healthcare provider who is licensed to prescribe medications. Healthcare providers must meet all federal requirements and shall conform to federal regulations related to naltrexone products.
- (c) Providers shall adhere to the prevailing federal and state requirements regarding the use of opioid treatment medications in the maintenance treatment of individuals who are or become pregnant during the course of treatment.

Rulemaking Authority 397.321(5), 397.21(5) FS. Law Implemented 397.311(26), 397.321, 397.410, 397.427, 397.311(18)(g), 397.321(1), 397.419, 465 FS. History–New 5-25-00, Amended 4-3-03, Amended

NAME OF PERSON ORIGINATING PROPOSED RULE: Ute Gazioch

NAME OF AGENCY HEAD WHO APPROVED THE PROPOSED RULE: Chad Poppell

DATE PROPOSED RULE APPROVED BY AGENCY HEAD: March 13, 2019

DATE NOTICE OF PROPOSED RULE DEVELOPMENT PUBLISHED IN FAR: August 24, 2018

## Section III Notice of Changes, Corrections and Withdrawals

#### REGIONAL PLANNING COUNCILS

Northeast Florida Regional Planning Council

RULE NO.: RULE TITLE: 29D-2.001 A-95 Review

NOTICE OF CORRECTION

Notice is hereby given that the following correction has been made to the proposed rule in Vol. 45 No. 54, March 19, 2019 issue of the Florida Administrative Register.

29D-2.001 A-95 Review.

Rulemaking Specific Authority 120.54, 163.01, 186.501 FS. Law Implemented 120.53(1), 163.01, FS. History-New 12-6-77, Repealed\_\_\_\_\_.

### Section IV Emergency Rules

#### **NONE**

## Section V Petitions and Dispositions Regarding Rule Variance or Waiver

DEPARTMENT OF BUSINESS AND PROFESSIONAL REGULATION

**Board of Professional Engineers** 

RULE NO.: RULE TITLE:

61G15-20.007 Educational Requirements for Applicants without EAC/ABET Accredited Engineering Degrees

The Board of Professional Engineers hereby gives notice: that the Petition filed by Sunita Nadella, on October 16, 2018, seeking a variance of subsection 61G15-20.007(5), F.A.C., has been withdrawn. The Notice of Petition was published in Vol. 44 No. 205 of the October 19, 2018, issue of the Florida Administrative Register. The Board considered the Petition at a duly-noticed public meeting held on December 6, 2018, in Tallahassee, Florida.

A copy of the Order or additional information may be obtained by contacting: Zana Raybon, Executive Director, Board of Professional Engineers, 2639 North Monroe Street, Suite B-112, Tallahassee, FL 32303, or telephone (850)521-0050 or by email: zraybon@fbpe.org.

### Section VI Notice of Meetings, Workshops and Public Hearings

## DEPARTMENT OF AGRICULTURE AND CONSUMER SERVICES

**Division of Consumer Services** 

The Florida Motor Vehicle Repair Advisory Council announces a telephone conference call to which all persons are invited.

DATE AND TIME: Tuesday, April 2, 2019, 1:30 p.m.

PLACE: Call-in number: 1(888)585-9008, participant code: 114-840-063#

GENERAL SUBJECT MATTER TO BE CONSIDERED: General meeting of the Florida Motor Vehicle Repair Advisory Council.

A copy of the agenda may be obtained by contacting: Amy Topol, Director, Division of Consumer Services, 2005 Apalachee Parkway, Tallahassee, Florida 32399-6500, (850)410-3800.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 3 days before the workshop/meeting by contacting: Amy Topol at (850)410-3800. If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

#### REGIONAL PLANNING COUNCILS

South Florida Regional Planning Council

The South Florida Regional Planning Council & The City of Dania Beach announces a public meeting to which all persons are invited.

DATE AND TIME: Wednesday, March 27, 2019, 5:00 p.m. – 7:00 p.m.

PLACE: City Hall, NW Conference Room, 100 W. Dania Beach Blvd., Dania Beach, FL 33004

GENERAL SUBJECT MATTER TO BE CONSIDERED: To discuss the preparedness of the City of Dania Beach for the new state statute of Peril of Flood. This meeting will discuss the implications of sea level rise, and storm surge as it pertains to Dania Beach's readiness to reduce flood risk and redevelop following a flood. Additionally, this meeting will allow the public to voice concerns and opinions regarding the subject matter.

A copy of the agenda may be obtained by contacting: The South Florida Regional Planning Council.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 1 days before the workshop/meeting by contacting: (954)924-3653. If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

If any person decides to appeal any decision made by the Board with respect to any matter considered at this meeting or hearing, he/she will need to ensure that a verbatim record of the proceeding is made, which record includes the testimony and evidence from which the appeal is to be issued.

For more information, you may contact: The South Regional Planning Council at (954)924-3653.

#### WATER MANAGEMENT DISTRICTS

members.

Southwest Florida Water Management District

The Southwest Florida Water Management District (SWFWMD) announces a public meeting to which all persons are invited.

DATE AND TIME: Tues., April 9, 2019, 1:30 p.m.

PLACE: District's Tampa Office, 7601 US Highway 301 North, Tampa, FL 33637

GENERAL SUBJECT MATTER TO BE CONSIDERED: Environmental Advisory Committee meeting: Discuss committee business. All or part of this meeting may be conducted by means of communications media technology in order to permit maximum participation of Governing Board

A copy of the agenda may be obtained by contacting: WaterMatters.org — Boards, Meetings & Event Calendar;1(800)423-1476 (FL only) or (352)796-7211.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 5 days before the workshop/meeting by contacting: SWFWMD Human Resources Office Chief at 1(800)423-1476 (FL only) or (352)796-7211, x4703; TDD (FL only) 1(800)231-6103; or email to ADACoordinator@swfwmd.state.fl.us. If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

If any person decides to appeal any decision made by the Board with respect to any matter considered at this meeting or hearing, he/she will need to ensure that a verbatim record of the proceeding is made, which record includes the testimony and evidence from which the appeal is to be issued.

For more information, you may contact: Lauren.Vossler@watermatters.org; 1(800)423-1476 (FL only) or (352)796-7211, x4605 (Ad Order EXE0672).

#### WATER MANAGEMENT DISTRICTS

Southwest Florida Water Management District

The Southwest Florida Water Management District (SWFWMD) announces a public meeting to which all persons are invited.

DATE AND TIME: Thursday, April 11, 2019, 10:00 a.m. PLACE: SWFWMD Tampa Office, 7601 US Highway 301 North, Tampa FL 33637

GENERAL SUBJECT MATTER TO BE CONSIDERED: Tampa Bay Cooperative Funding Initiative Public Meeting: Governing Board members will discuss, evaluate and prioritize fiscal year 2020 requests for project funding in Hillsborough, Pasco and Pinellas counties of SWFWMD. All or part of this meeting may be conducted by means of communications media technology to permit maximum participation of Governing Board members.

A copy of the agenda may be obtained by contacting: WaterMatters.org – Boards, Meetings & Event Calendar;1(800)423-1476 (FL only) or (352)796-7211.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 5 days before the workshop/meeting by contacting: SWFWMD Human Resources Office Chief at 1(800)423-1476 (FL only) or (352)796-7211, x4703; TDD (FL only) 1(800)231-6103; or email to ADACoordinator@swfwmd.state.fl.us. If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

If any person decides to appeal any decision made by the Board with respect to any matter considered at this meeting or hearing, he/she will need to ensure that a verbatim record of the proceeding is made, which record includes the testimony and evidence from which the appeal is to be issued.

For more information, you may contact: Lori.manuel@watermatters.org; 1(800)423-1476 (FL only) or (352)796-7211, x4606 (Ad Order EXE0673).

#### WATER MANAGEMENT DISTRICTS

Southwest Florida Water Management District

The Southwest Florida Water Management District (SWFWMD) announces a public meeting to which all persons are invited.

DATE AND TIME: Wednesday, April 10, 2019, 10:00 a.m. PLACE: SWFWMD Brooksville Office, 2379 Broad Street, Brooksville, FL 34604

GENERAL SUBJECT MATTER TO BE CONSIDERED: Northern Region Cooperative Funding Initiative Public Meeting: Governing Board members will discuss, evaluate and prioritize fiscal year 2020 requests for project funding in Citrus, Hernando, Lake, Levy, Marion and Sumter counties of SWFWMD. All or part of this meeting may be conducted by means of communications media technology to permit maximum participation of Governing Board members.

A copy of the agenda may be obtained by contacting: WaterMatters.org – Boards, Meetings & Event Calendar;1(800)423-1476 (FL only) or (352)796-7211

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 5 days before the workshop/meeting by contacting: SWFWMD Human Resources Office Chief at 1(800)423-1476 (FL only) or (352)796-7211, x4703; TDD (FL only) 1(800)231-6103; or email to ADACoordinator@swfwmd.state.fl.us. If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

If any person decides to appeal any decision made by the Board with respect to any matter considered at this meeting or hearing, he/she will need to ensure that a verbatim record of the proceeding is made, which record includes the testimony and evidence from which the appeal is to be issued.

For more information, you may contact: Lori.manuel@watermatters.org; 1(800)423-1476 (FL only) or (352)796-7211, x4606 (Ad Order EXE0674).

### DEPARTMENT OF BUSINESS AND PROFESSIONAL REGULATION

State Boxing Commission

The Florida State Boxing Commission announces a public meeting to which all persons are invited.

DATE AND TIME: April 27, 2019, 9:00 a.m.

PLACE: DoubleTree by Hilton Hotel Sunrise-Sawgrass Mills, Room: Tequesta Salon, 13400 West Sunrise Boulevard, Sunrise, FL 33323

GENERAL SUBJECT MATTER TO BE CONSIDERED: Conduct a general business meeting including license application review, discipline cases, and other miscellaneous matters.

A copy of the agenda may be obtained by contacting: Patrick Cunningham, Executive Director, Florida State Boxing Commission, 2601 Blair Stone Road, Tallahassee, FL 32399-1016 or (850)488-8500.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 24 hours before the workshop/meeting by contacting: Patrick Cunningham (850)488-8500. If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

If any person decides to appeal any decision made by the Board with respect to any matter considered at this meeting or hearing, he/she will need to ensure that a verbatim record of the proceeding is made, which record includes the testimony and evidence from which the appeal is to be issued.

For more information, you may contact: Patrick Cunningham (850)488-8500.

#### DEPARTMENT OF HEALTH

**Board of Nursing** 

The Board of Nursing announces a public meeting to which all persons are invited.

DATES AND TIMES: Wednesday, April 3, 2019, 1:30 p.m.; Thursday, April 4, 2019, 8:30 a.m.; Thursday,

April 4, 2019, 1:30 p.m.; Friday, April 5, 2019, 8:30 a.m.

PLACE: Embassy Suites Tampa- USF 3705 Spectrum Blvd. Tampa, Florida 33612

GENERAL SUBJECT MATTER TO BE CONSIDERED: Credential and Education Committee

meetings; Disciplinary Hearings and General Business

A copy of the agenda may be obtained by contacting: http://www.floridasnursing.gov/meeting-information.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 48 hours before the workshop/meeting by contacting: If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

If any person decides to appeal any decision made by the Board with respect to any matter considered at this meeting or hearing, he/she will need to ensure that a verbatim record of the proceeding is made, which record includes the testimony and evidence from which the appeal is to be issued.

#### DEPARTMENT OF HEALTH

Division of Emergency Preparedness and Community Support The Department of Health/EMS Advisory Council Access to Care Committee Meeting announces a telephone conference call to which all persons are invited.

DATE AND TIME: April 9, 2019, 3:00 p.m. – 4:00 p.m. Eastern Time

PLACE: Please join my meeting from your computer, tablet or smartphone.

https://www.gotomeeting.com/join/116611501

You can also dial in using your phone.

United States (Toll-free): 1(866)899-4679, United States: 1(646)749-3117, Access Code: 116-611-501

GENERAL SUBJECT MATTER TO BE CONSIDERED: EMS State Plan, Goals and Objectives

A copy of the agenda may be obtained by contacting: NA For more information, you may contact: Bonnie Anderson, (850)558-9544, Bonnie.Anderson@flhealth.gov.

#### DEPARTMENT OF HEALTH

Division of Emergency Preparedness and Community Support The Department of Health EMS Advisory Council Communications Committee Meeting announces a telephone conference call to which all persons are invited.

DATE AND TIME: April 2, 2019, 2:30 p.m. – 3:30 p.m. Eastern Time

PLACE: Please join my meeting from your computer, tablet or smartphone.

https://global.gotomeeting.com/join/974670389

You can also dial in using your phone.

United States (Toll Free): 1(877)568-4106, United States: 1(786)535-3219, Access Code: 974-670-389

Joining from a video-conferencing room or system?

Dial: 67.217.95.2##974670389, Cisco devices: 974670389@67.217.95.2

First GoToMeeting? Try a test session: http://link.gotomeeting.com/email-welcome

GENERAL SUBJECT MATTER TO BE CONSIDERED: EMS State Plan, Goals and Objectives

A copy of the agenda may be obtained by contacting: NA For more information, you may contact: Bonnie Anderson, (850)558-9544, Bonnie.Anderson@flhealth.gov.

#### DEPARTMENT OF CHILDREN AND FAMILIES

Economic Self-Sufficiency Program

RULE NO.: RULE TITLE:

65A-2.036 Optional State Supplementation Base Provider Rates and Program Standards

The Department of Children and Families announces a workshop to which all persons are invited.

DATE AND TIME: April 9, 2019, 10:00 a.m.

PLACE: Florida Department of Children and Families, 1317 Winewood Boulevard, Bldg. 3, Room 454A, Tallahassee, FL 32399-0700

GENERAL SUBJECT MATTER TO BE CONSIDERED: Proposed changes to Rule 65A-2.036, F.A.C.

A copy of the agenda may be obtained by contacting: Jodi Abramowitz at (850)717-4470 or Jodi.abramowitz@myflfamilies.com.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 2 days before the workshop/meeting by contacting: Jodi Abramowitz at (850)717-4470 or Jodi.abramowitz@myflfamilies.com. If you are hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

## FISH AND WILDLIFE CONSERVATION COMMISSION Marine Fisheries

The Florida Fish and Wildlife Conservation Commission announces a public meeting to which all persons are invited. DATE AND TIME: April 8, 2019, 6:00 p.m. – 8:00 p.m. CT PLACE: Destin Community Center, 101 Stahlman Avenue, Destin, Florida 32541

DATE AND TIME: April 16, 2019, 6:00 p.m. – 8:00 p.m. ET PLACE: Florida Fish & Wildlife Research Institute – Karen A. Steidinger Auditorium, 100 8th Avenue Southeast, St. Petersburg, Florida 33701

DATE AND TIME: April 17, 2019, 6:00 p.m. – 8:00 p.m. ET PLACE: City of Stuart – Commission Chambers, 121 SW Flagler Avenue, Stuart, Florida 34994

DATE AND TIME: April 18, 2019, 6:00 p.m. – 8:00 p.m. ET PLACE: Brannon Center, 105 South Riverside Drive, New Smyrna Beach, Florida 32168

DATE AND TIME: May 6, 2019, 6:00 p.m. – 8:00 p.m. ET PLACE: Keiser University – Ft. Lauderdale, Room #402B, 1500 NW 49th Street, Ft. Lauderdale, Florida 33309

DATE AND TIME: May 7, 2019, 6:00 p.m. – 8:00 p.m. ET PLACE: Harvey Government Center – BOCC Room, 1200 Truman Avenue, Key West, Florida 33040

DATE AND TIME: May 8, 2019, 6:00 p.m. – 8:00 p.m. ET PLACE: Founders Park Community Center, 87000 Overseas Highway, Islamorada, Florida 33036

GENERAL SUBJECT MATTER TO BE CONSIDERED: The Fish and Wildlife Conservation Commission is holding a series of public workshops to gather public input about management of the blackfin tuna fishery. Staff will provide a brief presentation about the fishery and gather feedback on future management of the fishery. All stakeholders interested in blackfin tuna management are encouraged to attend.

A copy of the agenda may be obtained by contacting: Jessica McCawley, at 2590 Executive Center Circle East, Suite 201, Tallahassee, Florida 32301, (850)487-0554.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this workshop/meeting is asked to advise the agency at least 5 days before the workshop/meeting by contacting: The ADA Coordinator, at (850)488-6411. If you are

hearing or speech impaired, please contact the agency using the Florida Relay Service, 1(800)955-8771 (TDD) or 1(800)955-8770 (Voice).

For more information, you may contact: Jessica McCawley, at 2590 Executive Center Circle East, Suite 201, Tallahassee, Florida 32301, (850)487-0554.

# Section VII Notice of Petitions and Dispositions Regarding Declaratory Statements

DEPARTMENT OF BUSINESS AND PROFESSIONAL REGULATION

**Building Code Administrators and Inspectors Board** NOTICE IS HEREBY GIVEN that the Board of Building Code Administrators and Inspectors has issued an order disposing of the petition for declaratory statement filed by Rune Lero on November 15, 2018. The following is a summary of the agency's disposition of the petition: The Notice of Petition for Declaratory Statement was published in Vol. 44, No. 232, of the November 30, 2018 Florida Administrative Register. The Petitioner sought clarification of subsection 468.604(2) and paragraphs 468.621(1)(g) and 468.621(1)(i), F.S. as they pertain to the licensing required to conduct virtual inspections. The Board considered the instant Petition at a duly-noticed public meeting held on February 7, 2019 in St. Petersburg, Florida. The Board's Order, filed on February 27, 2019, finds that a licensed building inspector operating as a private provider under the provisions of paragraph 553.791(1)(i), F.S. who conducts a virtual inspection of the type specifically identified above utilizing the smartphone application, web based, video guided, biometrically protected program as specifically described in the Petition and by sworn testimony of the Petitioner is not, ipso facto failing to lawfully execute the duties and responsibilities of their license nor are they failing to ensure compliance with applicable building codes or requirements.

A copy of the Order Disposing of the Petition for Declaratory Statement may be obtained by contacting: Robyn Barineau, Executive Director, Board of Building Code Administrators and Inspectors, 2601 Blair Stone Road, N12, Tallahassee, FL 32399-0790, (850)717-1394 or by electronic mail - Robyn.Barineau@myfloridalicense.com.

## DEPARTMENT OF FINANCIAL SERVICES Finance

NOTICE IS HEREBY GIVEN that the Florida Office of Financial Regulation has received the petition for declaratory statement from Pay Depot, LLC. The petition seeks the agency's opinion as to the applicability of Chapter 560, Florida Statutes, as it applies to the petitioner.

On 3/15/2019, the Florida Office of Financial Regulation (Consumer Finance) received a Petition for Declaratory Statement from Pay Depot, LLC. The petition seeks a declaratory statement from the Office whether its business model (to sell and buy Bitcoin and other virtual currencies through Bitcoin ATMs not directly linked or dependent on a third-party exchange to transfer or receive virtual currency to its customers,) falls under the Florida Money Transmitter Statute, Chapter 560, Florida Statutes.

A copy of the Petition for Declaratory Statement may be obtained by contacting: Agency Clerk, Office of Financial Regulation, P.O. Box 8050, Tallahassee, Florida 32314-8050, (850)410-9889, Agency.Clerk@flofr.com.

Please refer all comments to: Agency Clerk, Office of Financial Regulation, P.O. Box 8050, Tallahassee, Florida 32314-8050, (850)410-9889, Agency.Clerk@flofr.com.

# Section VIII Notice of Petitions and Dispositions Regarding the Validity of Rules

Notice of Petition for Administrative Determination has been filed with the Division of Administrative Hearings on the following rules:

#### NONE

Notice of Disposition of Petition for Administrative Determination has been filed with the Division of Administrative Hearings on the following rules:

#### NONE

# Section IX Notice of Petitions and Dispositions Regarding Non-rule Policy Challenges

#### **NONE**

# Section X Announcements and Objection Reports of the Joint Administrative Procedures Committee

#### **NONE**

# Section XI Notices Regarding Bids, Proposals and Purchasing

DEPARTMENT OF EDUCATION

Florida State University

NOTICE TO PROFESSIONAL CONSULTANTS

Florida State University, State of Florida, announces that Professional services are required in the discipline of mechanical, electrical, plumbing engineering and commissioning.

Project and Location: Minor Projects at Florida State University, Tallahassee, FL

Project Description: Professional services are required in the discipline of mechanical, electrical, plumbing engineering and commissioning. Minor projects are specific projects for construction, renovation, alterations or additions that have a basic construction budget estimated to be \$2,000,000 or less; or studies for which the fee for professional services is \$200,000 or less. Campus Service contracts for minor projects provide that the consultant will be available on an as-needed basis. The University intends to award multiple contracts for a three (3) year term beginning July 1, 2019. The University reserves the option to renew this contract for two (2) additional twelve (12) month periods.

Finalists will be provided with a description of the final review requirements and a copy of FSU's standard professional services agreement for minor projects. The Selection Committee may reject all proposals and stop the selection process at any time.

INSTRUCTIONS: Firms desiring to provide professional services shall utilize the online electronic sourcing portal to submit the required information for which they are applying. Firms shall complete the Florida State University "Professional Qualifi-cations Supplement," and provide a copy of the applicant's current Professional Regis-tra-tion Certificate from the appropriate governing board via the online electronic sourcing portal as described below. Documents must be uploaded to the portal and are not to exceed 40 pages. Submittals that do not comply with these requirements or do not include the requested data will not be considered Submissions must be uploaded by 3:00 p.m. ET, on Monday April 22, 2019. All applicants must be properly registered in the State of Florida to practice the required profession at the time of application. If the applicant is a corpora-tion, it must be properly chartered by the Florida Department of State to operate in Florida.

The Florida State University Project Fact Sheet may be obtained on line at https://www.facilities.fsu.edu/depts/designConstr/ or by contacting: James Johnson, Facilities Design & Construction,

969 Learning Way, Suite 107P, Mendenhall Building A, Florida State University, Tallahassee, Florida 32306-4152, telephone, (850)645-0407.

The plans and specifications for campus service projects are subject to reuse in accordance with the provisions of Section 287.055, Florida Statutes. As required by Section 287.133, Florida Statutes, a consultant may not submit a proposal for this project if it is on the convicted vendor list for a public entity crime committed within the past 36 months. The selected consultant must warrant that it will neither utilize the services of, nor contract with, any supplier, subcontractor, or consultant in excess of \$50,000.00 in connection with this project for a period of 36 months from the date of their being placed on the convicted vendor list.

### \*\*\*\*PLEASE CAREFULLY NOTE NEW SUBMITTAL INFORMATION\*\*\*\*

FSU utilizes an online electronic sourcing portal for accepting professional qualifications submittals and Architect Qualifications Supplement digitally. We do not accept hard copy submissions or submissions through other medium other than through FSU's Public Procurement Portal.

Your submission must be uploaded prior to the as indicated above. Note: We strongly recommend that you give yourself sufficient time and at least ONE (1) hour before the Closing date/time to begin the uploading process and to finalize your submission. Late submissions due to electronic uploading delays will not be considered.

- Each item of requested information is instantly sealed (no one from FSU can review) and will only be visible after the closing date/time. You may edit your submission as needed up to the closing date/time.
- Responders may elect to utilize the import/export feature to export questions into Excel in order to work on responses offline and import into the system upon completion.
- Keep in mind that when answering questions in the provided text box within the system (if applicable) there is a limit to the number of characters you can use in your response. The dynamic character limit counter at the bottom of each text box will display the remaining characters available.
- Uploading large documents may take significant time, depending on the size of the file(s) and your Internet connection speed. The maximum upload file size is 50 MB.
- Please do not embed any documents within your uploaded files, as they will not be accessible or evaluated.
- Information submitted that is not requested by FSU or in the specific format requested will be considered to be supplemental and not subject to evaluation.
- All sourcing event-related communications between vendors and FSU is managed and tracked through a Question and Answer Board within the RFQ event on the Public Procurement Portal. Any issues or questions related to logging

in or technical issues, including attachments, can be submitted to our third party software host, Jaggaer via a Support form: https://www.jaggaer.com/service-support/supplier-support/ or by calling 1(800)233-1121, option 2 then option 2.

Applications that do not comply with the above instructions will not be considered. Application material will not be returned.

## Section XII Miscellaneous

#### DEPARTMENT OF STATE

Index of Administrative Rules Filed with the Secretary of State Pursuant to subparagraph 120.55(1)(b)6. – 7., F.S., the below list of rules were filed in the Office of the Secretary of State between 3:00 p.m., Wednesday, March 13, 2019 and 3:00 p.m., Tuesday, March 19, 2019.

Rule No.	File Date	Effective
		Date
5L-1.002	3/13/2019	4/2/2019
5L-1.008	3/13/2019	4/2/2019
5L-1.009	3/13/2019	4/2/2019
5L-1.010	3/13/2019	4/2/2019
5L-1.013	3/13/2019	4/2/2019
5L-1.015	3/13/2019	4/2/2019
5L-1.017	3/13/2019	4/2/2019
5P-3.003	3/18/2019	4/7/2019
5P-3.006	3/18/2019	4/7/2019
61H1-20.0093	3/15/2019	4/4/2019
64B3-5.003	3/14/2019	4/3/2019
64B13-15.006	3/14/2019	4/3/2019
64B16-26.351	3/15/2019	4/4/2019
64B16-26.400	3/15/2019	4/4/2019
64B16-28.110	3/15/2019	4/4/2019
64B16-30.003	3/15/2019	4/4/2019
64B33-2.003	3/15/2019	4/4/2019

LIST OF RULES AWAITING LEGISLATIVE APPROVAL SECTIONS 120.541(3), 373.139(7) AND/OR 373.1391(6), FLORIDA STATUTES

Rule No.	File Date	Effective Date
60FF1-5.009	7/21/2016	**/**/***
64B8-10.003	12/9/2015	**/**/***
69L-3.009	12/5/2018	**/**/***

#### AGENCY FOR HEALTH CARE ADMINISTRATION

Health Facility and Agency Licensing

North Okaloosa Medical Center

The Agency for Health Care Administration has received an application for an emergency service exemption from North Okaloosa Medical Center located at 151 E Redstone Ave, Crestview, FL 32539-5352 pursuant to subsection 395.1041 (3), Florida Statutes and 59A-3.255, Florida Administrative Code. The hospital is requesting an emergency service exemption for Otolaryngology/ENT. Comments received within 15 days of publication will be considered by the Agency prior to making a determination of exemption status.

Additional information may be obtained by writing to the Agency for Health Care Administration, Attention: Julie Young, 2727 Mahan Drive, MS # 31, Tallahassee, Florida 32308, by phone at (850)412-4549 or by e-mail at Julie.Young@ahca.myflorida.com.

### FISH AND WILDLIFE CONSERVATION COMMISSION

Freshwater Fish and Wildlife

Nontraditional Section 6 (NTS6) grants program

The Florida Fish and Wildlife Conservation Commission is soliciting proposals for its Nontraditional Section 6 (NTS6) grants program [68-1.003(13), F.A.C.]. The NTS6 grants are awarded to non-federal entities or individuals interested in furthering conservation of federally listed species through Habitat Conservation Planning (HCP), HCP Land Acquisitions, and Recovery Land Acquisitions. A copy of the federal RFP can be found at: https://www.grants.gov/web/grants/searchgrants.html searching for Opportunity bv Number F19AS00144. FWCs grant rule can be found https://www.flrules.org/gateway/ruleNo.asp?id=68-1.003;

links to the NTS6 grant guidelines and associated documents regarding process and timeline for application submission can be found in the rule language. Applications for grant funding will be accepted beginning March 20, 2019. Applications must be received by FWC before close of business on May 4, 2019. Applications received after the deadline will be ineligible for consideration. For more information, email: Tom.Ostertag@MyFWC.com or call (850)921-1033.

## Section XIII Index to Rules Filed During Preceding Week

NOTE: The above section will be published on Tuesday beginning October 2, 2012, unless Monday is a holiday, then it will be published on Wednesday of that week.